NCT05363059

Brief Summary

Bariatric surgery (BS) is known to improve the components of metabolic syndrome (MS) in obese patients. However, few studies have evaluated the impact of bariatric surgery versus medical therapy (MT) in patients with MS, especially in patients with low body mass index (BMI). This study aimed to assess the effect of bariatric surgery on MS in patients with low BMI by comparing BS (BMI\<35 kg/m2 and BMI≥35 kg/m2) with MT (BMI\<35 kg/m2). A retrospective study including patients with MS undergoing bariatric surgery and medical therapy at a single institution. We follow up the 5 years effect of bariatric surgery versus medical therapy on the remission of MS, its individual components, atherosclerotic cardiovascular disease (ASCVD) risk, and medication used.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2010

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2010

Completed
12 years until next milestone

First Submitted

Initial submission to the registry

April 18, 2022

Completed
17 days until next milestone

First Posted

Study publicly available on registry

May 5, 2022

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2024

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2024

Completed
Last Updated

August 20, 2024

Status Verified

August 1, 2024

Enrollment Period

14.4 years

First QC Date

April 18, 2022

Last Update Submit

August 16, 2024

Conditions

Keywords

metabolic syndromeMedical therapyBariatric surgerybody mass index

Outcome Measures

Primary Outcomes (2)

  • Change in metabolic parameters from baseline to 5 years.

    Waist circumference(cm)

    baseline to 5 years

  • Change in metabolic parameters from baseline to 5 years.

    body mass index(kg/m\^2)

    baseline to 5 years

Secondary Outcomes (7)

  • Change in glycosylated hemoglobin from baseline to 5 years.

    baseline to 5 years

  • Change in plasma glucose from baseline to 5 years.

    baseline to 5 years

  • Change in blood lipids from baseline to 5 years.

    baseline to 5 years

  • Changes of CVD risk

    baseline to 5 years

  • Hypoglycemic drugs use

    baseline to 5 years

  • +2 more secondary outcomes

Study Arms (2)

BS group

The group of bariatric surgery therapy in metabolic syndrome patients.

Procedure: Bariatric surgery

MT group

The group of medical therapy in metabolic syndrome patients

Drug: Hypoglycemic drugs

Interventions

drug

Also known as: antihypertensive drugs, lipid-lowering drugs
MT group

surgery

Also known as: metabolic surgery
BS group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients underwent bariatric surgery or medical therapy for metabolic syndrome between 2010 and 2020 at our institution.

You may qualify if:

  • BMI\<35 kg/m\^2
  • Underwent bariatric surgery or medical therapy
  • Patients met the diagnostic criteria for MS, defined criteria derived from the joint interim statement (JIS)

You may not qualify if:

  • Patients who failed to follow up
  • Insulin dependent diabetes
  • congenital dementia
  • brain trauma
  • epileps
  • severe hypoglycemic coma
  • cerebrovascular disease
  • ischemic
  • heart disease
  • renal dysfunction
  • alcohol abuse
  • mental illness
  • psychoactive substance abuse
  • unwillingness to provide informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stryker Laparoscopy

Chongqing, Chongqing Municipality, 400042, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Plasma

MeSH Terms

Conditions

Metabolic Syndrome

Interventions

Hypoglycemic AgentsAntihypertensive AgentsBariatric Surgery

Condition Hierarchy (Ancestors)

Insulin ResistanceHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Physiological Effects of DrugsPharmacologic ActionsChemical Actions and UsesCardiovascular AgentsTherapeutic UsesBariatricsObesity ManagementTherapeuticsSurgical Procedures, Operative

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director, Center for Hypertension and Metabolic Diseases, Department of Hypertension and Endocrinology, Daping Hospital

Study Record Dates

First Submitted

April 18, 2022

First Posted

May 5, 2022

Study Start

May 1, 2010

Primary Completion

September 30, 2024

Study Completion

December 30, 2024

Last Updated

August 20, 2024

Record last verified: 2024-08

Data Sharing

IPD Sharing
Will not share

Locations